{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.4","upperLimit":"64.7","value":"59.2"},{"groupId":"OG001","lowerLimit":"51.6","upperLimit":"63.0","value":"57.4"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.4","upperLimit":"65.7","value":"60.1"},{"groupId":"OG001","lowerLimit":"53.3","upperLimit":"64.6","value":"59.0"}]}],"title":"2 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"Overall Hematologic Response (OHR) was defined as CHR, NEL or minor hematologic response (MiHR). CHR was defined as: WBC ≤ ULN; ANC ≥ 1,000/mm\\^3; - platelets ≥ 100,000/mm\\^3; - no blasts or promyelocytes in PB; BM blasts ≤ 5%; \\< 5% myelocytes plus metamyelocytes in PB; basophils in PB \\< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets ≥ 20,000/mm\\^3 and \\< 100,000/mm\\^3; ANC \\> 500/mm\\^3 and \\<1,000/mm\\^3. MiHR defined as: \\< 15% blasts in BM and in PB; \\< 30% blasts + promyelocytes in BM and PB; \\< 20% basophils in PB; No extra-medullary disease other than spleen and liver. Percentage: participants with OHR/ randomized participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"Participants were analyzed based on the treatment they were randomized to receive.","reportingStatus":"POSTED","timeFrame":"Randomization up to 6 Months, 2 Years","title":"Percent of Participants With Overall Hematologic Response - Randomized Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}